Profile data is unavailable for this security.
About the company
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
- Revenue in USD (TTM)52.60m
- Net income in USD-485.50m
- Incorporated2014
- Employees526.00
- LocationIntellia Therapeutics Inc40 Erie St Ste 130CAMBRIDGE 02139-4254United StatesUSA
- Phone+1 (857) 285-6200
- Fax+1 (302) 655-5049
- Websitehttps://www.intelliatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 1.94bn | 268.00 | -- | 4.38 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 1.96bn | 436.00 | -- | 2.15 | -- | 5.43 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 1.97bn | 500.00 | -- | 4.90 | -- | 42.56 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 1.97bn | 186.00 | -- | 2.77 | -- | 24.81 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Myriad Genetics, Inc. | 774.20m | -234.60m | 2.06bn | 2.70k | -- | 2.71 | -- | 2.66 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.06bn | 7.70k | -- | -- | 19.36 | 0.8263 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.06bn | 526.00 | -- | 1.99 | -- | 39.21 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.06bn | 383.00 | -- | 2.77 | -- | 70.17 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.07bn | 1.76k | 14.59 | 3.07 | 10.30 | 3.06 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.08bn | 55.00 | -- | 5.85 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Geron Corp | 520.00k | -201.40m | 2.11bn | 141.00 | -- | 6.04 | -- | 4,049.27 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.11bn | 1.54k | -- | -- | -- | 2.12 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| CG Oncology Inc | 539.00k | -72.33m | 2.17bn | 61.00 | -- | 3.82 | -- | 4,028.08 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.18bn | 226.00 | -- | 35.32 | -- | 23.67 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.18bn | 570.00 | -- | 5.32 | -- | 7.97 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Data as of May 31 2024. Currency figures normalised to Intellia Therapeutics Inc's reporting currency: US Dollar USD
51.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 10.99m | 11.40% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.93m | 9.26% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.54m | 7.82% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.60m | 4.77% |
| Deep Track Capital LPas of 31 Mar 2024 | 4.21m | 4.37% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 4.16m | 4.32% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 3.40m | 3.53% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.04m | 2.12% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.01m | 2.09% |
| Federated Global Investment Management Corp.as of 31 Mar 2024 | 1.93m | 2.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
